Healthcare Services

Global Nontuberculous Mycobacterial Infection Market Set for Strong Expansion, Reaching $21.01 Billion With 7.3% CAGR by 2030

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nontuberculous mycobacterial infection market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Nontuberculous Mycobacterial Infection Market’s size between 2026 and 2030?

The nontuberculous mycobacterial infection market size has experienced strong growth in recent years. This market is set to expand from $14.96 billion in 2025 to $15.87 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.1%. The historical increase in the market can be ascribed to a high incidence of pulmonary infections, limited effective therapies, delayed diagnosis of nontuberculous mycobacteria, reliance on conventional antibiotic regimens, and low awareness among clinicians.

The nontuberculous mycobacterial infection market is anticipated to experience substantial growth in the upcoming years, with its size projected to reach $21.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. This expansion over the forecast period is driven by the escalating adoption of macrolide and rifampin combination therapies, greater availability of aminoglycosides, the proliferation of personalized treatment strategies, the widening reach of hospital and specialty pharmacy networks, and the innovation of AI-enabled monitoring and diagnostic instruments. Noteworthy trends during this period also comprise the increased uptake of macrolide and rifampin treatments, more extensive use of aminoglycoside-based regimens, the broader implementation of multi-drug protocols, the expanding utilization of sophisticated diagnostic tools, and the progressing incorporation of AI-powered treatment oversight.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

Which Drivers Are Shaping Strategic Decisions In The Nontuberculous Mycobacterial Infection Market?

The growing occurrence of chronic obstructive pulmonary disease (COPD) is projected to stimulate the expansion of the nontuberculous mycobacterial infection market in the future. COPD itself is a long-term respiratory ailment marked by ongoing and frequently worsening restrictions in lung airflow. When nontuberculous mycobacterial (NTM) infections affect individuals with COPD, they are linked to a more pronounced reduction in forced expiratory volume in one second (FEV1) and an elevated frequency of exacerbations. COPD can compromise the immune system and harm lung tissue, thereby facilitating NTM bacterial colonization of the lungs. As an illustration, in September 2024, data from Public Health Scotland, a government health agency based in Scotland, indicated that during 2022/23 in Scotland, the incidence of COPD, determined by hospital admissions and death records, stood at 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males. Consequently, the increasing occurrence of chronic obstructive pulmonary disease (COPD) is a key factor stimulating the expansion of the nontuberculous mycobacterial infection market.

What Segment Classifications Make Up The Nontuberculous Mycobacterial Infection Market?

The nontuberculous mycobacterial infection market covered in this report is segmented –

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin

2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy

3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin

4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine

Which Trends Are Shaping Activity Within The Nontuberculous Mycobacterial Infection Market?

Companies operating within the nontuberculous mycobacterial infection market are concentrating on developing advanced solutions, such as boron-based antibiotics, to boost treatment effectiveness, overcome drug resistance, and improve patient outcomes. These boron-based antibiotics are small-molecule therapies formulated to inhibit bacterial protein synthesis, providing powerful and safer options for persistent infections. For example, in September 2023, AN2 Therapeutics, a US-based biopharmaceutical company, started enrolling patients in the Phase 3 part of its pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory Mycobacterium avium complex lung disease, after having completed Phase 2 enrolments. Designed for oral administration, epetraborole demonstrated potential in preclinical studies to treat Mycobacterium abscessus infections, with the aim of reducing treatment duration, enhancing tolerability, and addressing unmet medical needs in rare and serious infectious lung diseases, thereby contributing to better patient outcomes and disease management.

Which Leading Companies Dominate The Nontuberculous Mycobacterial Infection Market Share?

Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Nontuberculous Mycobacterial Infection Market?

North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nontuberculous Mycobacterial Infection Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp

Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2026, By The Business Research Company

Rare Disease Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report

Tuberculosis Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/tuberculosis-diagnostics-global-market-report

Clinical Microbiology Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-microbiology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795